Don’t Shy Away From Discussing MPN Side Effects

Video

Patients being treated for a myeloproliferative neoplasm should be open with their care team about any side effects they experience, an expert said.

It is essential that patients being treated for a myeloproliferative neoplasm (MPN) be upfront with their clinicians about side effects that they experience, explained Julie Huynh-Lu, a physician assistant from The University of Texas MD Anderson Cancer Center in Houston.

MPNs neoplasms are a group of blood cancers that causes the bone marrow to produce too much red or white blood cells or platelets. While there are multiple treatments for MPNs depending on the patient’s characteristics and individual disease type, common side effects, according to Huynh-Lu, include diarrhea, frequent infections and pneumonia.

Patients may feel apprehensive about discussing side effects with their care team in fear of being taken off treatment. But they shouldn’t be, Huynh-Lu, explained.

“So sometimes it could be something as simple as putting a band-aid on it … let's say they started treatment and they're having worsening itching. Well, there's medications that I can use to treat the worsening itching,” Huynh-Lu said in an interview with CURE®. “If the drug is controlling their disease, then let's just put a band-aid on it and go from there. If they are having progression and disease, that's something different.”

If a patient’s disease is getting worse on treatment, there are options, too, such as switching to a different type of treatment or enrolling in a clinical trial, Huynh-Lu said.

Transcription

My advice probably would be if you're having these side effects, then the idea of being on treatment is to help you feel better, right? And not just prolonging your life and treating the disease — it's to improve your quality of life. So if you're having these symptoms, that honestly might be (worsening) your quality of life, then it certainly bodes having a conversation with your provider on whether or not the current treatment is the right one for you. Because there could be other options out there, and it's worth exploring; it doesn't mean necessarily that you have to jump ship and go straight to a different treatment, obviously, but it's worth it to discuss with someone, what else is out there, because you might not know what else is out there for yourself.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
A man with a dark gray button-up shirt with glasses and cropped brown hair.
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE
Dr. Barzi in an interview with CURE
Sue Friedman in an interview with CURE